Elisa Luño
MD, PHD, Specialist in Hematology at the Central University Hospital of Asturias (HUCA) and Professor at the University of Oviedo (UNIOVI). Expertise in Myelodysplastic Syndromes (MDS) among other Hemopathies, Cytology and Cytogenetic method (Optical and Ultrastructural morphology, Karyotype and FISH) applied to the diagnosis, prognosis and follow-up of Malignant Hemopathies. Author and/or co-author of numerous publications, communications and conferences about MDS, CLL, Lymphoma, morphology and/or Cytogenetic related among other topics
less
Related Authors
Interests
Uploads
Papers by Elisa Luño
developed, but its prognostic value in a large and independent series remains unproven. Furthermore, the intermediate-risk cytogenetic subgroup defined by the IPSS includes a miscellaneous number of different single abnormalities of uncertain prognostic significance at present. The main aim of the present study was to identify chromosomal
abnormalities with a previously unrecognized good or poor prognosis in order to find new cytogenetic markers with predictive value. Design and Methods. We report the cytogenetic findings in a series of 968 patients
with primary MDS from the Spanish Cytogenetics Working Group, Grupo Cooperativo Español de Citogenética Hematológica (GCECGH).
Results. In this series of 968 MDS patients, we found various cytogenetic aberrations with a new prognostic impact. Complex karyotype, -7/7q- and i(17q) had a poor prognosis; normal karyotype, loss of Y chromosome, deletion 11q, deletion 12p and deletion 20q as single alterations had a good prognosis. Intermediate prognosis aberrations were rearrangements of 3q21q26, trisomy 8, trisomy 9, translocations of 11q and del(17p). Finally, a new group of single or double cytogenetic abnormalities, most
of which are considered rare cytogenetic events and are usually included in the intermediate category of the IPSS, showed a trend to poor prognosis. Interpretations and Conclusions. This study suggests that some specific chromosomal abnormalities could be segregated from the IPSS intermediate-risk cytogenetic prognostic subgroup and included in the low risk or in the poor risk groups.
developed, but its prognostic value in a large and independent series remains unproven. Furthermore, the intermediate-risk cytogenetic subgroup defined by the IPSS includes a miscellaneous number of different single abnormalities of uncertain prognostic significance at present. The main aim of the present study was to identify chromosomal
abnormalities with a previously unrecognized good or poor prognosis in order to find new cytogenetic markers with predictive value. Design and Methods. We report the cytogenetic findings in a series of 968 patients
with primary MDS from the Spanish Cytogenetics Working Group, Grupo Cooperativo Español de Citogenética Hematológica (GCECGH).
Results. In this series of 968 MDS patients, we found various cytogenetic aberrations with a new prognostic impact. Complex karyotype, -7/7q- and i(17q) had a poor prognosis; normal karyotype, loss of Y chromosome, deletion 11q, deletion 12p and deletion 20q as single alterations had a good prognosis. Intermediate prognosis aberrations were rearrangements of 3q21q26, trisomy 8, trisomy 9, translocations of 11q and del(17p). Finally, a new group of single or double cytogenetic abnormalities, most
of which are considered rare cytogenetic events and are usually included in the intermediate category of the IPSS, showed a trend to poor prognosis. Interpretations and Conclusions. This study suggests that some specific chromosomal abnormalities could be segregated from the IPSS intermediate-risk cytogenetic prognostic subgroup and included in the low risk or in the poor risk groups.